|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BFAR |
Gene summary for BFAR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BFAR | Gene ID | 51283 |
| Gene name | bifunctional apoptosis regulator | |
| Gene Alias | BAR | |
| Cytomap | 16p13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | H3BMP2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51283 | BFAR | LZE4T | Human | Esophagus | ESCC | 2.07e-15 | 4.74e-01 | 0.0811 |
| 51283 | BFAR | LZE5T | Human | Esophagus | ESCC | 1.11e-02 | 1.47e-03 | 0.0514 |
| 51283 | BFAR | LZE8T | Human | Esophagus | ESCC | 2.51e-09 | 2.59e-01 | 0.067 |
| 51283 | BFAR | LZE20T | Human | Esophagus | ESCC | 5.38e-07 | 6.06e-02 | 0.0662 |
| 51283 | BFAR | LZE24T | Human | Esophagus | ESCC | 3.54e-11 | 3.29e-01 | 0.0596 |
| 51283 | BFAR | P1T-E | Human | Esophagus | ESCC | 2.06e-05 | 4.49e-01 | 0.0875 |
| 51283 | BFAR | P2T-E | Human | Esophagus | ESCC | 4.02e-50 | 1.16e+00 | 0.1177 |
| 51283 | BFAR | P4T-E | Human | Esophagus | ESCC | 6.80e-19 | 5.25e-01 | 0.1323 |
| 51283 | BFAR | P5T-E | Human | Esophagus | ESCC | 8.80e-21 | 3.46e-01 | 0.1327 |
| 51283 | BFAR | P8T-E | Human | Esophagus | ESCC | 1.84e-31 | 6.88e-01 | 0.0889 |
| 51283 | BFAR | P9T-E | Human | Esophagus | ESCC | 4.53e-18 | 2.95e-01 | 0.1131 |
| 51283 | BFAR | P10T-E | Human | Esophagus | ESCC | 1.50e-12 | 3.34e-01 | 0.116 |
| 51283 | BFAR | P11T-E | Human | Esophagus | ESCC | 3.81e-16 | 9.02e-01 | 0.1426 |
| 51283 | BFAR | P12T-E | Human | Esophagus | ESCC | 5.61e-39 | 9.61e-01 | 0.1122 |
| 51283 | BFAR | P15T-E | Human | Esophagus | ESCC | 4.38e-35 | 1.04e+00 | 0.1149 |
| 51283 | BFAR | P16T-E | Human | Esophagus | ESCC | 3.81e-46 | 1.04e+00 | 0.1153 |
| 51283 | BFAR | P17T-E | Human | Esophagus | ESCC | 3.68e-03 | 5.27e-01 | 0.1278 |
| 51283 | BFAR | P19T-E | Human | Esophagus | ESCC | 1.36e-07 | 7.59e-01 | 0.1662 |
| 51283 | BFAR | P20T-E | Human | Esophagus | ESCC | 1.07e-45 | 1.10e+00 | 0.1124 |
| 51283 | BFAR | P21T-E | Human | Esophagus | ESCC | 1.29e-31 | 7.53e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00359667 | Liver | Cirrhotic | response to topologically incorrect protein | 91/4634 | 159/18723 | 2.07e-18 | 3.60e-16 | 91 |
| GO:00069867 | Liver | Cirrhotic | response to unfolded protein | 79/4634 | 137/18723 | 1.99e-16 | 2.49e-14 | 79 |
| GO:00359677 | Liver | Cirrhotic | cellular response to topologically incorrect protein | 64/4634 | 116/18723 | 2.20e-12 | 1.62e-10 | 64 |
| GO:00346207 | Liver | Cirrhotic | cellular response to unfolded protein | 54/4634 | 96/18723 | 4.16e-11 | 2.42e-09 | 54 |
| GO:00309686 | Liver | Cirrhotic | endoplasmic reticulum unfolded protein response | 43/4634 | 74/18723 | 9.86e-10 | 4.48e-08 | 43 |
| GO:19058977 | Liver | Cirrhotic | regulation of response to endoplasmic reticulum stress | 46/4634 | 82/18723 | 1.28e-09 | 5.56e-08 | 46 |
| GO:007093611 | Liver | Cirrhotic | protein K48-linked ubiquitination | 36/4634 | 65/18723 | 1.23e-07 | 3.41e-06 | 36 |
| GO:19035737 | Liver | Cirrhotic | negative regulation of response to endoplasmic reticulum stress | 26/4634 | 44/18723 | 1.30e-06 | 2.59e-05 | 26 |
| GO:000020911 | Liver | Cirrhotic | protein polyubiquitination | 89/4634 | 236/18723 | 6.09e-06 | 9.80e-05 | 89 |
| GO:19001015 | Liver | Cirrhotic | regulation of endoplasmic reticulum unfolded protein response | 19/4634 | 30/18723 | 8.57e-06 | 1.27e-04 | 19 |
| GO:19001022 | Liver | Cirrhotic | negative regulation of endoplasmic reticulum unfolded protein response | 10/4634 | 15/18723 | 7.26e-04 | 5.36e-03 | 10 |
| GO:00364983 | Liver | Cirrhotic | IRE1-mediated unfolded protein response | 10/4634 | 19/18723 | 8.23e-03 | 3.83e-02 | 10 |
| GO:1903894 | Liver | Cirrhotic | regulation of IRE1-mediated unfolded protein response | 8/4634 | 14/18723 | 9.65e-03 | 4.35e-02 | 8 |
| GO:00705342 | Liver | Cirrhotic | protein K63-linked ubiquitination | 22/4634 | 56/18723 | 1.14e-02 | 4.96e-02 | 22 |
| GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
| GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
| GO:003497612 | Liver | HCC | response to endoplasmic reticulum stress | 189/7958 | 256/18723 | 1.43e-24 | 4.06e-22 | 189 |
| GO:003596612 | Liver | HCC | response to topologically incorrect protein | 123/7958 | 159/18723 | 2.60e-19 | 3.44e-17 | 123 |
| GO:000698612 | Liver | HCC | response to unfolded protein | 103/7958 | 137/18723 | 6.50e-15 | 4.48e-13 | 103 |
| GO:003596712 | Liver | HCC | cellular response to topologically incorrect protein | 89/7958 | 116/18723 | 5.61e-14 | 3.39e-12 | 89 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BFAR | SNV | Missense_Mutation | c.643N>G | p.Leu215Val | p.L215V | Q9NZS9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| BFAR | insertion | In_Frame_Ins | novel | c.1254_1255insACAAGGACA | p.Val418_Cys419insThrArgThr | p.V418_C419insTRT | Q9NZS9 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| BFAR | insertion | In_Frame_Ins | novel | c.1255_1256insTCAGCACGG | p.Cys419delinsPheSerThrGly | p.C419delinsFSTG | Q9NZS9 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| BFAR | insertion | Frame_Shift_Ins | rs781267226 | c.763dupC | p.Gln255ProfsTer7 | p.Q255Pfs*7 | Q9NZS9 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| BFAR | SNV | Missense_Mutation | novel | c.407C>T | p.Ala136Val | p.A136V | Q9NZS9 | protein_coding | tolerated(0.29) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BFAR | SNV | Missense_Mutation | rs746810685 | c.1182N>C | p.Trp394Cys | p.W394C | Q9NZS9 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BFAR | SNV | Missense_Mutation | c.1040N>A | p.Phe347Tyr | p.F347Y | Q9NZS9 | protein_coding | tolerated(0.14) | probably_damaging(0.989) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| BFAR | SNV | Missense_Mutation | c.547N>G | p.Thr183Ala | p.T183A | Q9NZS9 | protein_coding | tolerated(0.09) | benign(0.018) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BFAR | SNV | Missense_Mutation | c.656N>A | p.Thr219Lys | p.T219K | Q9NZS9 | protein_coding | tolerated(0.25) | possibly_damaging(0.602) | TCGA-CA-6715-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
| BFAR | SNV | Missense_Mutation | rs777625063 | c.1327C>T | p.Arg443Trp | p.R443W | Q9NZS9 | protein_coding | deleterious(0.01) | possibly_damaging(0.828) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |